Corrigendum to 'Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer': [ESMO Open. Volume 11, Issue 2, February 2026, 106057].
APA
Lee JB, Kim KH, et al. (2026). Corrigendum to 'Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer': [ESMO Open. Volume 11, Issue 2, February 2026, 106057].. ESMO open, 11(4), 106919. https://doi.org/10.1016/j.esmoop.2026.106919
MLA
Lee JB, et al.. "Corrigendum to 'Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer': [ESMO Open. Volume 11, Issue 2, February 2026, 106057].." ESMO open, vol. 11, no. 4, 2026, pp. 106919.
PMID
41812621
같은 제1저자의 인용 많은 논문 (4)
- A Phase 2 Study of Stereotactic Ablative Radiotherapy Plus Atezolizumab Plus Tiragolumab in Treatment-naïve Patients with Advanced Non-small Cell Lung Cancer.
- Spatially Controlled Capture and Site-Resolved Analysis of Single Extracellular Vesicles.
- Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer.
- Lower facial contouring surgery using a novel method: M-genioplasty.